Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
Primary Objectives:
1. To determine the toxicity profile of multiple doses of bortezomib when given with ICE in
patients with relapsed and refractory classical Hodgkin lymphoma (HL).
2. To determine the maximum tolerated dose (MTD) of bortezomib when given in combination
with ICE chemotherapy in patients with relapsed and refractory classical Hodgkin
lymphoma (HL).
Secondary Objectives:
- To determine the overall response rate and complete response rate in patients with relapsed
and refractory classical Hodgkin lymphoma (HL).